The COVID-19 pandemic continues to wreak havoc and even after more than 2 years having passed since the report of the first infected patient, there has not been any approved treatment. Several vaccines, though approved, are not widely available for all age groups and those with different comorbidities (Vabret et al., 2020). In this scenario, immune modulation is considered as the major strategy to combat the infection, and different agents have been employed in this regard (Zhong et al., 2020). Immunotherapies are at various stages of development aiming at augmented antiviral immunity with a particular focus on the innate immune response to not only enhance it but also modulate it in a balanced manner to prevent hyperimmune activation (Schijns & Lavelle, 2020).

Beta (β)-glucans have been suggested to be potential nonspecific immunostimulatory adjuvants to beneficially boost protective antiviral immunity. Through this article, we wish to emphasize that β-glucans not only enhance the innate immunity but also possess the capability to modulate all the arms of the immunity viz., innate, adaptive, TRIM at different sites including those postulated to be the entry site of the SARS-CoV2. Other than immune modulation capabilities, the beneficial metabolic- and coagulation-related effects of β-glucans, a simple nutritional supplementation strategy, make them be considered for larger clinical studies to validate their prophylactic vaccine adjuvant and nutritional-based therapeutic supplement activities to effectively fight the COVID-19 pandemic.

Practical applications
A 360° wholesome protection from viral infections is possible only when all the arms of the immune system function in a balanced and effective manner which is especially important in COVID-19. Nutritional supplementation using biological response modifier beta (β)-glucans (BRMGs) is worth considering for large-scale clinical studies based on their track record of safety and their beneficial regulation of all the arms of the immune system.

KEYWORDS
antiviral, beta (β)-glucans, COVID-19, immune modulation, innate immunity
and safety in bringing down the inflammatory and immune biomarkers associated with cytokine storm and coagulopathy in COVID-19 patients (Pushkala et al., 2021; Raghavan et al., 2022).

We wish to emphasize that these β-glucans not only promote TRIM and innate immunity but also have capabilities to uniquely modulate all the arms of the immunity viz., innate, adaptive, TRIM at different sites, including those postulated to be the entry site of the SARS-CoV2, the mucosal and gut immunity (Ikewaki, Iwasaki, et al., 2020). Although yeast-based β-glucans have been proven clinically to be safe and effective vaccine adjuvants, especially an AFO-202-derived β-glucans against Avian Influenza virus (Le et al., 2011), the significance of this β-glucan as a wide-spectrum immune enhancement (β-WIFE) vaccine adjuvant strategy to COVID-19 (Ikewaki et al., 2021) deserves a mention.

Such β-glucans modulate all arms of the immunity in a controlled manner through the following postulated mechanisms:

1. Induce epigenetic reprogramming both at the peripheral and at the central level of bone marrow, leading to cellular activation of trained innate immune cells for antiviral activity, with a long-lasting innate memory (Geller & Yan, 2020).
2. β-glucans activate antigen-presenting dendritic cells (DCs), leading to stimulation of antigen-specific CD4 and CD8 T cells, and induce IFN-γ production (Netea et al., 2020).
3. Since the β-glucans act akin to pathogen-associated molecular patterns (PAMP), activating mucosal and gut immunity by binding with specific pathogen recognition receptors such as dectin-1, which is also a key receptor for beta (β)-glucan binding, this process induces adaptive and innate immunity in distant lymphoid organs as well (Li et al., 2010).
4. Acts on B cell-mediated adaptive immune response by increasing the immunoglobulins specifically those in the saliva (sgM, sgG, and sgA), as they can mount effective anti-SARS-CoV2 response at the level of oral entry itself. Orally administered β-glucans also have been reported to stabilize IgG1 levels, maintaining anti-infective immunity (Richter et al., 2016).
5. A balanced immune modulation occurs after the administration of β-glucans with the enhancement of beneficial cytokines such as IL-7, IFN-γ, and sFAS while suppression of pro-inflammatory cytokine storm-inducing cytokines such as IL-6 (Netea et al., 2020). These processes occurring in diabetic patients due to constant glucose recognition by C-type lectin receptors and immune-related coagulatory dysfunction pose individuals with these metabolic alterations at heightened risk of severe mortality associated with the disease (Ikewaki, Rao, et al., 2020).

Thus, by adopting a simple nutritional supplementation strategy based on β-glucans, not only the innate immune response is beneficially enhanced but all arms of the immunity including at the postulated sites of entry of the SARS-CoV2 virus are also modulated in a controlled and effective manner. Therefore, we suggest that this β-glucan-based controlled immune modulation strategy be considered for large-scale multicentric clinical trials for validation as a prophylactic vaccine adjuvant and nutritional-based therapeutic supplement strategy to effectively fight the COVID-19 pandemic, in a manner that has minimal adverse effects which are considered the major hurdle for several disease-fighting strategies under development for COVID-19.

CONFLICT OF INTEREST
Samuel Abraham is a shareholder in GN Corporation, Japan which in turn is a shareholder in the manufacturing company of the AFO 202 Beta Glucan product and an applicant to several patents of relevance.

AUTHOR CONTRIBUTIONS
Nobunao Ikewaki: Conceptualization; writing – review and editing. Gene Kurosawa: Writing – review and editing. Tomohiko Kisaka: Writing – review and editing. Samuel JK Abraham: Conceptualization; writing – original draft.

DATA AVAILABILITY STATEMENT
Data sharing is not applicable to this article as no data sets were generated or analyzed during the current study.

ORCID
Samuel J. K. Abraham https://orcid.org/0000-0003-2646-2687

REFERENCES
Geller, A., & Yan, J. (2020). Could the induction of trained immunity by β-Glucan serve as a defense against COVID-19? Frontiers in Immunology, 11, 1782.
Ikewaki, N., Iwasaki, M., & Abraham, S. J. K. (2020). Biological response modifier glucan through balancing of blood glucose may have a prophylactic potential in COVID-19 patients. Journal of Diabetes and Metabolic Disorders, 19, 1-4.
Ikewaki, N., Iwasaki, M., Kurosawa, G., Rao, K. S., Lakey-Beitia, J., Preethy, S., & Abraham, S. J. (2021). β-Glucans: Wide-spectrum immune-balancing food-supplement-based enteric (β-WIFE) vaccine adjuvant approach to COVID-19. Human Vaccines & Immunotherapeutics, 17, 1–6.
Ikewaki, N., Rao, K. S., Archibold, A. D., Iwasaki, M., Senthilkumar, R., Preethy, S., Katoh, S., & Abraham, S. J. K. (2020). Coagulopathy associated with COVID-19—Perspectives & Preventive strategies using a biological response modifier Glucan. Thrombosis Journal, 18, 27.
Jayachandran, M., Chen, J., Chung, S. S. M., & Xu, B. (2018). A critical review on the impacts of β-glucans on gut microbiota and human health. The Journal of Nutritional Biochemistry, 61, 101–110.
Le, T., Le, T., Doan, T. H., Quyen, D., Le, K. X., Pham, V., Nagataki, M., Nomura, H., Ikeue, Y., Watanabe, Y., & Agatsuma, T. (2011). The adjuvant effect of Sophy β-glucan to the antibody response in poultry immunized by the avian influenza a H5N1 and H5N2 vaccines. *Journal of Microbiology and Biotechnology, 21*, 405–411.

Li, B., Cai, Y., Qi, C., Hansen, R., Ding, C., Mitchell, T. C., & Yan, J. (2010). Orally administered particulate beta-glucan modulates tumor-capturing dendritic cells and improves antitumor T-cell responses in cancer. *Clinical Cancer Research, 16*, 5153–5164.

Netea, M. G., Domínguez-Andrés, J., Barreiro, L. B., Chavakis, T., Divangahi, M., Fuchs, E., Joosten, L. A. B., van der Meer, J. W. M., Mihanga, M. M., Mulder, W. J. M., Riksen, N. P., Schlitzer, A., Schultze, J. L., Stabell Benn, C., Sun, J. C., Xavier, R. J., & Latz, E. (2020). Defining trained immunity and its role in health and disease. *Nature Reviews. Immunology, 20*, 375–388.

Pushkala, S., Seshayyan, S., Theranirajan, E., Sudhakar, D., Raghavan, K., Dedeepiya, V. D., Ikewaki, N., Iwasaki, M., Preethy, S., & Abraham, S. (2021). Efficient control of IL-6, CRP and ferritin in Covid-19 patients with two variants of Beta-1,3-1,6 glucans in combination, within 15 days in an open-label prospective clinical trial. *medRxiv, 21267778. https://doi.org/10.1101/December*

Raghavan, K., Dedeepiya, V. D., Yamamoto, N., Ikewaki, N., Sonoda, T., Kurosawa, G., Iwasaki, M., Kandaswamy, R., Senthilkumar, R., Preethy, S., & Abraham, S. J. K. (2021). Beneficial effects of novel Aureobasidium pullulans strains produced beta-1,3-1,6 glucans on interleukin-6 and D-dimer levels in COVID-19 patients: results of a randomized multiple-arm pilot clinical study. *Biomedicine & Pharmacotherapy, 145*, 112243.

Raghavan, K., Dedeepiya, V. D., Yamamoto, N., Ikewaki, N., Sonoda, T., Kurosawa, G., Iwasaki, M., Kandaswamy, R., Senthilkumar, R., Preethy, S., & Abraham, S. J. K. (2021). Beneficial reconstitution of gut microbiota and control of alpha-synuclein and curli-amyloids-producing enterobacteria, by beta 1,3-1,6 glucans in a clinical pilot study of autism and potentials in neurodegenerative diseases. *medRxiv, 21265505. https://doi.org/10.1101/October*

Richter, J., Kral, V., Vetvicka, V., Rajnohova, D. L., & Fernandez-Botran, R. (2016). Effect of β-glucan supplementation on levels of IgM, IgA, IgG and its subclasses IgG1, IgG2, IgG3, and IgG4 in cancer patients. *Journal of Tumor, 4*, 469–473.

Schijns, V., & Lavelle, E. C. (2020). Prevention and treatment of COVID-19 disease by controlled modulation of innate immunity. *European Journal of Immunology, 50*, 932–938.

Vabret, N., Britton, G. J., Gruber, C., Hegde, S., Kim, J., Kuksin, M., Levantovsky, R., Malle, L., Moreira, A., Park, M. D., Pia, L., Risson, E., Saffern, M., Salomé, B., Esai Selvan, M., Spindler, M. P., Tan, J., van der Heide, V., Gregory, J. K., … Samstein, R. M. (2020). Sinai immunology review project. Immunology of COVID-19: Current state of the science. *Immunity, 52*, 910–941.

Zhong, J., Tang, J., Ye, C., & Dong, L. (2020). The immunology of COVID-19: Is immune modulation an option for treatment? *Lancet Rheumatol., 2*, e428–e436.